Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NKTR NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKTRNektar Therapeutics$70.68-0.1%$65.52$21.02▼$109.00$2.39B1.13837,203 shs982,927 shsURGNUrogen Pharma$40.45-1.1%$34.57$15.86▼$43.93$1.99B1.56744,508 shs317,741 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKTRNektar Therapeutics-0.13%+1.96%+8.09%-16.89%+208.51%URGNUrogen Pharma-1.05%-3.83%+12.14%+69.74%+114.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKTRNektar Therapeutics$70.68-0.1%$65.52$21.02▼$109.00$2.39B1.13837,203 shs982,927 shsURGNUrogen Pharma$40.45-1.1%$34.57$15.86▼$43.93$1.99B1.56744,508 shs317,741 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKTRNektar Therapeutics-0.13%+1.96%+8.09%-16.89%+208.51%URGNUrogen Pharma-1.05%-3.83%+12.14%+69.74%+114.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNKTRNektar Therapeutics 2.75Moderate Buy$150.00112.22% UpsideURGNUrogen Pharma 2.80Moderate Buy$41.632.90% UpsideCurrent Analyst Ratings BreakdownLatest URGN and NKTR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2026NKTRNektar Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$153.007/21/2026URGNUrogen Pharma GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $42.007/17/2026URGNUrogen Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026URGNUrogen Pharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $50.007/15/2026URGNUrogen Pharma The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$44.007/9/2026URGNUrogen Pharma UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/9/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.006/2/2026NKTRNektar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/2/2026URGNUrogen Pharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/18/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.00(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNKTRNektar Therapeutics$55.23M43.24N/AN/A$4.41 per share16.03URGNUrogen Pharma$109.79M17.95N/AN/A($2.25) per share-17.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNKTRNektar Therapeutics-$164.08M-$8.42N/AN/AN/A-284.18%-85.40%-39.99%8/6/2026 (Estimated)URGNUrogen Pharma-$153.49M-$2.75N/A24.97N/A-94.83%N/A-62.85%8/6/2026 (Estimated)Latest URGN and NKTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026NKTRNektar Therapeutics-$1.94N/AN/AN/A$10.43 millionN/A8/6/2026Q2 2026URGNUrogen Pharma-$0.2650N/AN/AN/A$63.55 millionN/A5/7/2026Q1 2026NKTRNektar Therapeutics-$1.5824-$1.82-$0.2377-$1.82$10.69 million$10.86 million5/7/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNKTRNektar TherapeuticsN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNKTRNektar TherapeuticsN/A10.2110.21URGNUrogen PharmaN/A4.694.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNKTRNektar Therapeutics75.88%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipNKTRNektar Therapeutics2.50%URGNUrogen Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNKTRNektar Therapeutics22033.79 million32.94 millionOptionableURGNUrogen Pharma20048.72 million46.38 millionOptionableURGN and NKTR HeadlinesRecent News About These CompaniesUrogen Pharma (URGN) to Announce Quarterly Earnings on Thursday11 minutes ago | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Sells 738,026 Shares of Urogen Pharma $URGN1 hour ago | marketbeat.comUroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 20262 hours ago | markets.businessinsider.comAlly Bridge Group NY LLC Purchases Shares of 202,124 Urogen Pharma $URGNJuly 29 at 3:04 AM | marketbeat.comADAR1 Capital Management LLC Boosts Stock Position in Urogen Pharma $URGNJuly 29 at 3:03 AM | marketbeat.comUrogen Pharma (NASDAQ:URGN) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 29 at 2:15 AM | americanbankingnews.comUrogen Pharma (NASDAQ:URGN) Receives Average Rating of "Moderate Buy" from AnalystsJuly 29 at 2:13 AM | marketbeat.comElmind Capital LP Has $3.96 Million Position in Urogen Pharma $URGNJuly 28 at 4:00 AM | marketbeat.comUrogen Pharma (NASDAQ:URGN) Reaches New 12-Month High - Here's What HappenedJuly 21, 2026 | marketbeat.comUroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow MoatJuly 20, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT)July 17, 2026 | theglobeandmail.comShort sellers are betting against UroGen Pharma stock, but Wall Street expects 263% earnings growth in 2027July 17, 2026 | msn.comUroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ...July 15, 2026 | caledonianrecord.comCUroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103July 15, 2026 | globenewswire.comUrogen Pharma (NASDAQ:URGN) Reaches New 52-Week High - What's Next?July 15, 2026 | marketbeat.comUroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% RunJuly 12, 2026 | fool.comUrogen Pharma (NASDAQ:URGN) Insider Sells 10,000 SharesJuly 11, 2026 | insidertrades.comUrogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 SharesJuly 10, 2026 | marketbeat.comUroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder CancerJuly 8, 2026 | globenewswire.comUrogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?July 7, 2026 | zacks.comIs UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?June 30, 2026 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeURGN and NKTR Company DescriptionsNektar Therapeutics NASDAQ:NKTR$70.68 -0.09 (-0.13%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$69.72 -0.96 (-1.35%) As of 06:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Urogen Pharma NASDAQ:URGN$40.45 -0.43 (-1.05%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$40.47 +0.02 (+0.05%) As of 05:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
